Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Business Wire•29/10/2026•06:30 ET
0
Key Highlights
- ➤Worldwide sales $18.1 billion, up 5% year over year
- ➤Non-GAAP EPS $2.49, down 3% from third quarter 2025
- ➤WINREVAIR sales $694 million, up 93% year over year
- ➤2026 sales outlook narrowed and raised to $66.8 billion-$67.3 billion
- ➤FDA accepted sac-TMT’s endometrial-cancer BLA; PDUFA date set for June 15, 2027
Expert Statements
Robert M. Davis, Chairman and Chief Executive Officer of Merck & Co., Inc.
“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Sales Growth Reflects Continued Strength in Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR
Get started
Create a free account to read the full story.